{"doi":"10.1002/ueg2.12268","title":"LIAISON<sup>®</sup> Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non‐inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON<jats:sup>®</jats:sup> Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut‐off the area under the curve was 0.619, and the sensitivity was 62.9% (95% Confidence Interval [CI] 44.9%–78.5%) and specificity 63.0% (95% CI 53.1%–72.1%). Using machine learning methods, the last FC measurement was shown to have the largest impact in predicting relapse. An algorithm was developed that included other variables available following a clinician's visit, which resulted in an area under the curve of 0.754 for predicting relapse.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In the present study FC measured by the LIAISON<jats:sup>®</jats:sup> Calprotectin assay on the visit before relapse is predictive of relapse in patients with quiescent UC. In a proof of concept, the accuracy of prediction can further be improved including other variables in an algorithm developed by machine learning.</jats:p></jats:sec><jats:sec><jats:title>Trial registration</jats:title><jats:p>The trial is registered at <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">clinicaltrials.gov</jats:ext-link> with reference number NCT05168917.</jats:p></jats:sec>","journal":"United European Gastroenterology Journal","year":2022,"id":630222,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":240771,"name":"Silvio Danese","orcid":"0000-0001-7341-1351","position":1,"is_corresponding":false},{"id":233519,"name":"Laurent Peyrin‐Biroulet","orcid":"0000-0003-2536-6618","position":2,"is_corresponding":false},{"id":546975,"name":"Miquel Sans","orcid":"0000-0003-3081-7516","position":3,"is_corresponding":false},{"id":1632526,"name":"Fabrizio Bonelli","orcid":null,"position":4,"is_corresponding":false},{"id":1632527,"name":"Mariella Calleri","orcid":null,"position":5,"is_corresponding":false},{"id":1632528,"name":"Claudia Zierold","orcid":"0000-0002-7898-0470","position":6,"is_corresponding":false},{"id":1632530,"name":"Roberta Pollastro","orcid":null,"position":7,"is_corresponding":false},{"id":1632531,"name":"Fabio Moretti","orcid":null,"position":8,"is_corresponding":false},{"id":1632532,"name":"Alberto Malesci","orcid":null,"position":9,"is_corresponding":false},{"id":1225507,"name":"Gionata Fiorino","orcid":"0000-0001-5623-2968","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"LIAISON<sup>®</sup> Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non‐inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON<jats:sup>®</jats:sup> Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut‐off the area under the curve was 0.619, and the sensitivity was 62.9% (95% Confidence Interval [CI] 44.9%–78.5%) and specificity 63.0% (95% CI 53.1%–72.1%). Using machine learning methods, the last FC measurement was shown to have the largest impact in predicting relapse. An algorithm was developed that included other variables available following a clinician's visit, which resulted in an area under the curve of 0.754 for predicting relapse.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In the present study FC measured by the LIAISON<jats:sup>®</jats:sup> Calprotectin assay on the visit before relapse is predictive of relapse in patients with quiescent UC. In a proof of concept, the accuracy of prediction can further be improved including other variables in an algorithm developed by machine learning.</jats:p></jats:sec><jats:sec><jats:title>Trial registration</jats:title><jats:p>The trial is registered at <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">clinicaltrials.gov</jats:ext-link> with reference number NCT05168917.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35789124","pmcid":"PMC9557957","openalex_id":"https://openalex.org/W4283805183","authors":[],"funders":[],"total_grants":0,"fwci":1.5122,"citation_percentile":0.82959217,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":5},{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1002/ueg2.12268","host_type":"journal"},{"url":"https://doi.org/10.1002/ueg2.12268","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ueg2.12268","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ueg2.12268","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35789124","host_type":"repository"},{"url":"https://hal.univ-lorraine.fr/hal-04168200","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9557957","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9557957","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9557957?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Inflammatory Bowel Disease","Microscopic Colitis","S100 Proteins and Annexins","Biomarkers","Colitis, Ulcerative","Feces","Humans","Leukocyte L1 Antigen Complex","Longitudinal Studies","Prospective Studies","Recurrence"],"mesh_terms":["Colitis, Ulcerative","Feces","Humans","Longitudinal Studies","Prospective Studies","Recurrence","Biomarkers","Leukocyte L1 Antigen Complex"],"keywords":["Medicine","Calprotectin","Confidence interval","Ulcerative colitis","Internal medicine","Gastroenterology","Clinical trial","Colitis","Faecal calprotectin","Prospective cohort study","Feces","Inflammatory bowel disease","Disease","Algorithm","Relapse","Machine Learning","Flare"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T20:42:15.169466Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}